Brokerages Set Attovia Therapeutics, Inc. (NASDAQ:ATTO) Target Price at $42.20

Attovia Therapeutics, Inc. (NASDAQ:ATTO) has been assigned a consensus rating of “Moderate Buy” from the six research firms that are presently covering the firm, MarketBeat Ratings reports. One research analyst has rated the stock with a hold rating and five have given a buy rating to the company. The average 12 month price objective among analysts that have updated their coverage on the stock in the last year is $42.20.

A number of brokerages have recently issued reports on ATTO. Leerink Partners started coverage on shares of Attovia Therapeutics in a research report on Monday, August 31st. They set an “outperform” rating and a $52.00 target price on the stock. Citigroup started coverage on shares of Attovia Therapeutics in a research note on Monday, August 31st. They set a “buy” rating and a $30.00 price target for the company. Royal Bank Of Canada assumed coverage on shares of Attovia Therapeutics in a research report on Monday, August 31st. They set an “outperform” rating and a $45.00 price objective on the stock. Zacks Research upgraded shares of Attovia Therapeutics to a “hold” rating in a research note on Friday, September 4th. Finally, Lifesci Capital assumed coverage on shares of Attovia Therapeutics in a report on Monday, August 31st. They issued an “outperform” rating and a $45.00 target price for the company.

Insider Activity

In related news, major shareholder Goldman Sachs Group Inc acquired 500,000 shares of the firm’s stock in a transaction on Thursday, August 6th. The stock was bought at an average cost of $17.00 per share, with a total value of $8,500,000.00. Following the transaction, the insider owned 3,020,632 shares of the company’s stock, valued at $51,350,744. The trade was a 19.84% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, major shareholder Redmile Group, Llc bought 400,000 shares of the stock in a transaction on Thursday, August 6th. The stock was bought at an average price of $17.00 per share, for a total transaction of $6,800,000.00. Following the completion of the purchase, the insider directly owned 1,182,854 shares in the company, valued at approximately $20,108,518. The trade was a 51.10% increase in their position. The SEC filing for this purchase provides additional information. Over the last 90 days, insiders have bought 2,740,587 shares of company stock valued at $47,269,979.

Attovia Therapeutics Price Performance

Shares of NASDAQ ATTO opened at $23.70 on Wednesday. Attovia Therapeutics has a 52-week low of $16.15 and a 52-week high of $28.00.

Attovia Therapeutics (NASDAQ:ATTO) last released its quarterly earnings results on Wednesday, September 2nd. The company reported ($4.88) EPS for the quarter. The business had revenue of $0.45 million during the quarter. On average, sell-side analysts anticipate that Attovia Therapeutics will post -4.06 EPS for the current fiscal year.

Attovia Therapeutics Company Profile

Attovia Therapeutics, Inc (NASDAQ: ATTO) is a clinical-stage biotechnology company focused on developing antibody-based medicines for immune-mediated and inflammatory diseases. Its research programs are designed to address conditions in which dysregulated immune signaling contributes to disease.

The company’s activities include discovering, developing and advancing biologic drug candidates through preclinical and clinical testing. Attovia’s pipeline is centered on targeted therapies intended to modulate key pathways involved in inflammation and immune responses, with the goal of treating patients with significant unmet medical needs.

Attovia Therapeutics is headquartered in the United States and operates as a development-stage biopharmaceutical company.